Pharmaceutical Co. SteadyMed Misses Target With $40M IPO
SteadyMed Ltd., a venture capital-backed, California- and Israel-based specialty pharmaceutical company focused on rare diseases, raised $40 million in an downsized initial public offering Friday, coming in below earlier projections after...To view the full article, register now.
Already a subscriber? Click here to view full article